Cargando…
A VISION Substudy of Reader Agreement on (68)Ga-PSMA-11 PET/CT Scan Interpretation to Determine Patient Eligibility for (177)Lu-PSMA-617 Radioligand Therapy
[ (68)Ga]Ga-PSMA-11 ( (68)Ga-PSMA-11) is used to identify prostate-specific membrane antigen (PSMA)–positive tumors on PET scans. In the VISION study, (68)Ga-PSMA-11 was used to determine the eligibility of patients with metastatic castration-resistant prostate cancer for treatment with [(177)Lu]Lu-...
Autores principales: | , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Society of Nuclear Medicine
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10394308/ https://www.ncbi.nlm.nih.gov/pubmed/37230533 http://dx.doi.org/10.2967/jnumed.122.265077 |
_version_ | 1785083344298442752 |
---|---|
author | Kuo, Phillip H. Yoo, Don C. Avery, Ryan Seltzer, Marc Calais, Jeremie Nagarajah, James Weber, Wolfgang A. Fendler, Wolfgang P. Hofman, Michael S. Krause, Bernd J. Brackman, Marcia Kpamegan, Euloge Ghebremariam, Samson Benson, Taylor Catafau, Ana M. Kendi, Ayse T. |
author_facet | Kuo, Phillip H. Yoo, Don C. Avery, Ryan Seltzer, Marc Calais, Jeremie Nagarajah, James Weber, Wolfgang A. Fendler, Wolfgang P. Hofman, Michael S. Krause, Bernd J. Brackman, Marcia Kpamegan, Euloge Ghebremariam, Samson Benson, Taylor Catafau, Ana M. Kendi, Ayse T. |
author_sort | Kuo, Phillip H. |
collection | PubMed |
description | [ (68)Ga]Ga-PSMA-11 ( (68)Ga-PSMA-11) is used to identify prostate-specific membrane antigen (PSMA)–positive tumors on PET scans. In the VISION study, (68)Ga-PSMA-11 was used to determine the eligibility of patients with metastatic castration-resistant prostate cancer for treatment with [(177)Lu]Lu-PSMA-617 ((177)Lu-PSMA-617), based on predefined read criteria. This substudy aimed to investigate the interreader variability and intrareader reproducibility of visual assessments of (68)Ga-PSMA-11 PET/CT scans using the VISION read criteria and evaluate the agreement between read results for this and the VISION study. Methods: In VISION, (68)Ga-PSMA-11 PET/CT scans were centrally read as inclusion cases if they had at least 1 PSMA-positive lesion and no PSMA-negative lesions that fulfilled the exclusion criteria. In this substudy, 125 PET/CT scans (75 inclusion and 50 exclusion cases) were randomly selected from VISION and retrospectively assessed by 3 independent central readers. A random subset of 20 cases (12 inclusion and 8 exclusion cases) was recoded for assessment of intrareader reproducibility. Classification of cases as inclusion or exclusion cases was based on the VISION read criteria. Overall interreader variability was assessed by Fleiss κ-statistics, and pairwise variability and intrareader reproducibility were assessed by Cohen κ-statistics. Results: For interreader variability, the readers agreed on 77% of cases (overall average agreement rate, 0.85; Fleiss κ, 0.60 [95% CI, 0.50–0.70]). The pairwise agreement rate was 0.82, 0.88, and 0.84, and the corresponding Cohen κ was 0.54 (95% CI, 0.38–0.71), 0.67 (95% CI, 0.52–0.83), and 0.59 (95% CI, 0.43–0.75), respectively. For intrareader reproducibility, the agreement rate was 0.90, 0.90, and 0.95, and the corresponding Cohen κ was 0.78 (95% CI, 0.49–0.99), 0.76 (95% CI, 0.46–0.99), and 0.89 (95% CI, 0.67–0.99), respectively. The number of actual VISION inclusion cases out of the total number of cases scored as inclusion in this substudy was 71 of 93 (agreement rate, 0.76; 95% CI, 0.66–0.85) for reader 1, 70 of 88 (0.80; 0.70–0.87) for reader 2, and 73 of 96 (0.76; 0.66–0.84) for reader 3. All readers agreed on 66 of 75 VISION inclusion cases. Conclusion: Moderate-to-substantial interreader agreement and substantial-to-almost perfect intrareader reproducibility for (68)Ga-PSMA-11 PET/CT scan assessment using the VISION read criteria were observed. The read rules applied in VISION can be readily learned and demonstrate good reproducibility. |
format | Online Article Text |
id | pubmed-10394308 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Society of Nuclear Medicine |
record_format | MEDLINE/PubMed |
spelling | pubmed-103943082023-08-03 A VISION Substudy of Reader Agreement on (68)Ga-PSMA-11 PET/CT Scan Interpretation to Determine Patient Eligibility for (177)Lu-PSMA-617 Radioligand Therapy Kuo, Phillip H. Yoo, Don C. Avery, Ryan Seltzer, Marc Calais, Jeremie Nagarajah, James Weber, Wolfgang A. Fendler, Wolfgang P. Hofman, Michael S. Krause, Bernd J. Brackman, Marcia Kpamegan, Euloge Ghebremariam, Samson Benson, Taylor Catafau, Ana M. Kendi, Ayse T. J Nucl Med Clinical Investigation [ (68)Ga]Ga-PSMA-11 ( (68)Ga-PSMA-11) is used to identify prostate-specific membrane antigen (PSMA)–positive tumors on PET scans. In the VISION study, (68)Ga-PSMA-11 was used to determine the eligibility of patients with metastatic castration-resistant prostate cancer for treatment with [(177)Lu]Lu-PSMA-617 ((177)Lu-PSMA-617), based on predefined read criteria. This substudy aimed to investigate the interreader variability and intrareader reproducibility of visual assessments of (68)Ga-PSMA-11 PET/CT scans using the VISION read criteria and evaluate the agreement between read results for this and the VISION study. Methods: In VISION, (68)Ga-PSMA-11 PET/CT scans were centrally read as inclusion cases if they had at least 1 PSMA-positive lesion and no PSMA-negative lesions that fulfilled the exclusion criteria. In this substudy, 125 PET/CT scans (75 inclusion and 50 exclusion cases) were randomly selected from VISION and retrospectively assessed by 3 independent central readers. A random subset of 20 cases (12 inclusion and 8 exclusion cases) was recoded for assessment of intrareader reproducibility. Classification of cases as inclusion or exclusion cases was based on the VISION read criteria. Overall interreader variability was assessed by Fleiss κ-statistics, and pairwise variability and intrareader reproducibility were assessed by Cohen κ-statistics. Results: For interreader variability, the readers agreed on 77% of cases (overall average agreement rate, 0.85; Fleiss κ, 0.60 [95% CI, 0.50–0.70]). The pairwise agreement rate was 0.82, 0.88, and 0.84, and the corresponding Cohen κ was 0.54 (95% CI, 0.38–0.71), 0.67 (95% CI, 0.52–0.83), and 0.59 (95% CI, 0.43–0.75), respectively. For intrareader reproducibility, the agreement rate was 0.90, 0.90, and 0.95, and the corresponding Cohen κ was 0.78 (95% CI, 0.49–0.99), 0.76 (95% CI, 0.46–0.99), and 0.89 (95% CI, 0.67–0.99), respectively. The number of actual VISION inclusion cases out of the total number of cases scored as inclusion in this substudy was 71 of 93 (agreement rate, 0.76; 95% CI, 0.66–0.85) for reader 1, 70 of 88 (0.80; 0.70–0.87) for reader 2, and 73 of 96 (0.76; 0.66–0.84) for reader 3. All readers agreed on 66 of 75 VISION inclusion cases. Conclusion: Moderate-to-substantial interreader agreement and substantial-to-almost perfect intrareader reproducibility for (68)Ga-PSMA-11 PET/CT scan assessment using the VISION read criteria were observed. The read rules applied in VISION can be readily learned and demonstrate good reproducibility. Society of Nuclear Medicine 2023-08 /pmc/articles/PMC10394308/ /pubmed/37230533 http://dx.doi.org/10.2967/jnumed.122.265077 Text en © 2023 by the Society of Nuclear Medicine and Molecular Imaging. https://creativecommons.org/licenses/by/4.0/Immediate Open Access: Creative Commons Attribution 4.0 International License (CC BY) allows users to share and adapt with attribution, excluding materials credited to previous publications. License: https://creativecommons.org/licenses/by/4.0/. Details: http://jnm.snmjournals.org/site/misc/permission.xhtml. |
spellingShingle | Clinical Investigation Kuo, Phillip H. Yoo, Don C. Avery, Ryan Seltzer, Marc Calais, Jeremie Nagarajah, James Weber, Wolfgang A. Fendler, Wolfgang P. Hofman, Michael S. Krause, Bernd J. Brackman, Marcia Kpamegan, Euloge Ghebremariam, Samson Benson, Taylor Catafau, Ana M. Kendi, Ayse T. A VISION Substudy of Reader Agreement on (68)Ga-PSMA-11 PET/CT Scan Interpretation to Determine Patient Eligibility for (177)Lu-PSMA-617 Radioligand Therapy |
title | A VISION Substudy of Reader Agreement on (68)Ga-PSMA-11 PET/CT Scan Interpretation to Determine Patient Eligibility for (177)Lu-PSMA-617 Radioligand Therapy |
title_full | A VISION Substudy of Reader Agreement on (68)Ga-PSMA-11 PET/CT Scan Interpretation to Determine Patient Eligibility for (177)Lu-PSMA-617 Radioligand Therapy |
title_fullStr | A VISION Substudy of Reader Agreement on (68)Ga-PSMA-11 PET/CT Scan Interpretation to Determine Patient Eligibility for (177)Lu-PSMA-617 Radioligand Therapy |
title_full_unstemmed | A VISION Substudy of Reader Agreement on (68)Ga-PSMA-11 PET/CT Scan Interpretation to Determine Patient Eligibility for (177)Lu-PSMA-617 Radioligand Therapy |
title_short | A VISION Substudy of Reader Agreement on (68)Ga-PSMA-11 PET/CT Scan Interpretation to Determine Patient Eligibility for (177)Lu-PSMA-617 Radioligand Therapy |
title_sort | vision substudy of reader agreement on (68)ga-psma-11 pet/ct scan interpretation to determine patient eligibility for (177)lu-psma-617 radioligand therapy |
topic | Clinical Investigation |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10394308/ https://www.ncbi.nlm.nih.gov/pubmed/37230533 http://dx.doi.org/10.2967/jnumed.122.265077 |
work_keys_str_mv | AT kuophilliph avisionsubstudyofreaderagreementon68gapsma11petctscaninterpretationtodeterminepatienteligibilityfor177lupsma617radioligandtherapy AT yoodonc avisionsubstudyofreaderagreementon68gapsma11petctscaninterpretationtodeterminepatienteligibilityfor177lupsma617radioligandtherapy AT averyryan avisionsubstudyofreaderagreementon68gapsma11petctscaninterpretationtodeterminepatienteligibilityfor177lupsma617radioligandtherapy AT seltzermarc avisionsubstudyofreaderagreementon68gapsma11petctscaninterpretationtodeterminepatienteligibilityfor177lupsma617radioligandtherapy AT calaisjeremie avisionsubstudyofreaderagreementon68gapsma11petctscaninterpretationtodeterminepatienteligibilityfor177lupsma617radioligandtherapy AT nagarajahjames avisionsubstudyofreaderagreementon68gapsma11petctscaninterpretationtodeterminepatienteligibilityfor177lupsma617radioligandtherapy AT weberwolfganga avisionsubstudyofreaderagreementon68gapsma11petctscaninterpretationtodeterminepatienteligibilityfor177lupsma617radioligandtherapy AT fendlerwolfgangp avisionsubstudyofreaderagreementon68gapsma11petctscaninterpretationtodeterminepatienteligibilityfor177lupsma617radioligandtherapy AT hofmanmichaels avisionsubstudyofreaderagreementon68gapsma11petctscaninterpretationtodeterminepatienteligibilityfor177lupsma617radioligandtherapy AT krauseberndj avisionsubstudyofreaderagreementon68gapsma11petctscaninterpretationtodeterminepatienteligibilityfor177lupsma617radioligandtherapy AT brackmanmarcia avisionsubstudyofreaderagreementon68gapsma11petctscaninterpretationtodeterminepatienteligibilityfor177lupsma617radioligandtherapy AT kpameganeuloge avisionsubstudyofreaderagreementon68gapsma11petctscaninterpretationtodeterminepatienteligibilityfor177lupsma617radioligandtherapy AT ghebremariamsamson avisionsubstudyofreaderagreementon68gapsma11petctscaninterpretationtodeterminepatienteligibilityfor177lupsma617radioligandtherapy AT bensontaylor avisionsubstudyofreaderagreementon68gapsma11petctscaninterpretationtodeterminepatienteligibilityfor177lupsma617radioligandtherapy AT catafauanam avisionsubstudyofreaderagreementon68gapsma11petctscaninterpretationtodeterminepatienteligibilityfor177lupsma617radioligandtherapy AT kendiayset avisionsubstudyofreaderagreementon68gapsma11petctscaninterpretationtodeterminepatienteligibilityfor177lupsma617radioligandtherapy AT kuophilliph visionsubstudyofreaderagreementon68gapsma11petctscaninterpretationtodeterminepatienteligibilityfor177lupsma617radioligandtherapy AT yoodonc visionsubstudyofreaderagreementon68gapsma11petctscaninterpretationtodeterminepatienteligibilityfor177lupsma617radioligandtherapy AT averyryan visionsubstudyofreaderagreementon68gapsma11petctscaninterpretationtodeterminepatienteligibilityfor177lupsma617radioligandtherapy AT seltzermarc visionsubstudyofreaderagreementon68gapsma11petctscaninterpretationtodeterminepatienteligibilityfor177lupsma617radioligandtherapy AT calaisjeremie visionsubstudyofreaderagreementon68gapsma11petctscaninterpretationtodeterminepatienteligibilityfor177lupsma617radioligandtherapy AT nagarajahjames visionsubstudyofreaderagreementon68gapsma11petctscaninterpretationtodeterminepatienteligibilityfor177lupsma617radioligandtherapy AT weberwolfganga visionsubstudyofreaderagreementon68gapsma11petctscaninterpretationtodeterminepatienteligibilityfor177lupsma617radioligandtherapy AT fendlerwolfgangp visionsubstudyofreaderagreementon68gapsma11petctscaninterpretationtodeterminepatienteligibilityfor177lupsma617radioligandtherapy AT hofmanmichaels visionsubstudyofreaderagreementon68gapsma11petctscaninterpretationtodeterminepatienteligibilityfor177lupsma617radioligandtherapy AT krauseberndj visionsubstudyofreaderagreementon68gapsma11petctscaninterpretationtodeterminepatienteligibilityfor177lupsma617radioligandtherapy AT brackmanmarcia visionsubstudyofreaderagreementon68gapsma11petctscaninterpretationtodeterminepatienteligibilityfor177lupsma617radioligandtherapy AT kpameganeuloge visionsubstudyofreaderagreementon68gapsma11petctscaninterpretationtodeterminepatienteligibilityfor177lupsma617radioligandtherapy AT ghebremariamsamson visionsubstudyofreaderagreementon68gapsma11petctscaninterpretationtodeterminepatienteligibilityfor177lupsma617radioligandtherapy AT bensontaylor visionsubstudyofreaderagreementon68gapsma11petctscaninterpretationtodeterminepatienteligibilityfor177lupsma617radioligandtherapy AT catafauanam visionsubstudyofreaderagreementon68gapsma11petctscaninterpretationtodeterminepatienteligibilityfor177lupsma617radioligandtherapy AT kendiayset visionsubstudyofreaderagreementon68gapsma11petctscaninterpretationtodeterminepatienteligibilityfor177lupsma617radioligandtherapy |